Purpose Of Review: To review the current evidence on dysphagia in non-head and neck cancer, including its cause, prevalence, impact, management, and areas for future research.
Recent Findings: Dysphagia is widely recognised as a common and debilitating side-effect of head and neck cancer (HNC) and its treatment; however, minimal attention has been given to dysphagia in other cancer populations. Detailed data regarding the exact nature and prevalence of dysphagia are limited, in part because of the lack of any validated tools specifically for non-HNC patients. Dysphagia can be due to a variety of different causes in cancer patients. It can have a significant impact on physical and psychological wellbeing, and its management can be complex and multifactorial.
Summary: Preliminary evidence suggests that the prevalence of dysphagia in non-HNC patients may be high. Cancer patients are vulnerable and survivorship is a key component of cancer care, so further research is essential to better understand the problem and thus provide optimal care and outcomes for patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOO.0000000000000541 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer.
Radiat Oncol
January 2025
German Cancer Consortium (DKTK), partner site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Background: For radiotherapy of head and neck cancer (HNC) magnetic resonance imaging (MRI) plays a pivotal role due to its high soft tissue contrast. Moreover, it offers the potential to acquire functional information through diffusion weighted imaging (DWI) with the potential to personalize treatment. The aim of this study was to acquire repetitive DWI during the course of online adaptive radiotherapy on an 1.
View Article and Find Full Text PDFArtificial intelligence for image recognition in diagnosing oral and oropharyngeal cancer and leukoplakia.
Sci Rep
January 2025
Department of Otolaryngology Head and Neck Surgery, Technical University Munich, Munich, Germany.
Visual diagnosis is one of the key features of squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC), both subsets of head and neck squamous cell carcinoma (HNSCC) with a heterogeneous clinical appearance. Advancements in artificial intelligence led to Image recognition being introduced recently into large language models (LLMs) such as ChatGPT 4.0.
View Article and Find Full Text PDFRelationship between muscular mass, inflammatory status, tumor metabolic activity and oral intake in head and neck cancer at the outset of management.
Clin Nutr ESPEN
January 2025
Service d'orl et chirurgie cervico-faciale, CHU de Clermont-Ferrand, 58 rue Montalembert, 63000 Clermont-Ferrand, France; Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, INRAE, CRNH Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address:
Background And Aims: Patients with head and neck cancer (HNC) are often malnourished with a low muscular mass at the outset of management. This is thought to be mainly due to poor nutritional intake. The aim of this study was to assess the correlation between tumor metabolic activity, inflammatory status and body composition in HNC patients.
View Article and Find Full Text PDFExploration of symptom cluster patterns and their trajectory in esophageal cancer surgery patients.
Eur J Oncol Nurs
January 2025
Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, PR China. Electronic address:
Purpose: To investigate symptom burden and symptom cluster trajectories in patients undergoing surgery for esophageal cancer.
Methods: A convenience sample of 210 patients who underwent thoracoscopic surgery for esophageal cancer was included from July to December 2023. The symptoms of the patients were evaluated at the following time points: preoperatively (T0), 1-3 days postoperatively (T1), 7 days postoperatively (T2), 1 month postoperatively (T3), and 3 months postoperatively (T4).
Is postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma?
Oral Oncol
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University Taoyuan Taiwan Republic of China. Electronic address:
Background: The current NCCN guidelines advocate for the use of adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) in pT3N0 oral cavity squamous cell carcinoma (OCSCC). Here, we sought to evaluate whether postoperative RT/CRT may confer a survival advantage in pT3N0 patients who lack adverse pathological features.
Methods: A dataset of 852 pT3N0 OCSCC patients treated between 2018 and 2021 was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!